NEWS
New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries
Esperion (NASDAQ: ESPR) has launched a new digital marketing campaign called 'Lipid Lurkers' to educate patients about the risks of uncontrolled LDL cholesterol. The campaign uses animated characters to visually represent the unseen risk lurking in patients' artery walls. This initiative follows the recent FDA-approved label expansion for NEXLETOLand NEXLIZET, allowing Esperion to target over 70 million Americans with high LDL-C.
The digital-first strategy aims to reach adults diagnosed with high LDL-C who cannot take statins or optimize their statin therapy. Initial results show 190,000 clicks for more information in May 2024. The campaign emphasizes patient empowerment to 'Take Control of Their Lipid Lurkers' and is designed to increase awareness among the target audience through various digital channels
Esperion (NASDAQ: ESPR) has launched a new digital marketing campaign called 'Lipid Lurkers' to educate patients about the risks of uncontrolled LDL cholesterol. The campaign uses animated characters to visually represent the unseen risk lurking in patients' artery walls. This initiative follows the recent FDA-approved label expansion for NEXLETOLand NEXLIZET, allowing Esperion to target over 70 million Americans with high LDL-C.
The digital-first strategy aims to reach adults diagnosed with high LDL-C who cannot take statins or optimize their statin therapy. Initial results show 190,000 clicks for more information in May 2024. The campaign emphasizes patient empowerment to 'Take Control of Their Lipid Lurkers' and is designed to increase awareness among the target audience through various digital channels
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1233Followers
76Following
8687Visitors
Follow